SG Americas Securities LLC Has $1.30 Million Stake in Organon & Co. $OGN

Posted by George Bondi on Jul 4th, 2026

SG Americas Securities LLC lowered its position in shares of Organon & Co. (NYSE:OGN – Free Report) by 21.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 216,319 shares of the company’s stock after selling 59,767 shares during the quarter. SG Americas Securities LLC’s holdings in Organon & Co. were worth $1,296,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Foster Dykema Cabot & Partners LLC bought a new position in shares of Organon & Co. in the 3rd quarter worth about $29,000. Farther Finance Advisors LLC lifted its stake in shares of Organon & Co. by 87.8% in the 4th quarter. Farther Finance Advisors LLC now owns 4,349 shares of the company’s stock valued at $31,000 after purchasing an additional 2,033 shares during the period. Eurizon Capital SGR S.p.A. bought a new stake in shares of Organon & Co. during the 4th quarter valued at about $44,000. Kestra Advisory Services LLC bought a new stake in shares of Organon & Co. during the 4th quarter valued at about $47,000. Finally, Empowered Funds LLC acquired a new stake in Organon & Co. during the fourth quarter worth approximately $74,000. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Price Performance

Shares of OGN opened at $13.56 on Friday. The business’s fifty day moving average is $13.27 and its 200 day moving average is $9.53. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.60. The company has a quick ratio of 1.42, a current ratio of 1.97 and a debt-to-equity ratio of 9.47. The stock has a market cap of $3.56 billion, a P/E ratio of 14.59, a P/E/G ratio of 1.25 and a beta of 1.54.

Organon & Co. (NYSE:OGN – Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The company reported $0.71 EPS for the quarter, missing analysts’ consensus estimates of $0.83 by ($0.12). Organon & Co. had a net margin of 3.99% and a return on equity of 99.95%. The business had revenue of $1.46 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same quarter last year, the firm posted $1.02 EPS. The business’s revenue for the quarter was down 3.5% compared to the same quarter last year. Sell-side analysts anticipate that Organon & Co. will post 3.23 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 11th. Stockholders of record on Monday, May 11th were given a dividend of $0.02 per share. The ex-dividend date of this dividend was Monday, May 11th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. Organon & Co.’s payout ratio is presently 8.60%.

Analysts Set New Price Targets

OGN has been the subject of a number of research analyst reports. Zacks Research upgraded Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Weiss Ratings upgraded Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. BNP Paribas Exane restated a “neutral” rating and set a $14.00 price target (up from $12.00) on shares of Organon & Co. in a report on Wednesday, April 29th. Finally, Piper Sandler raised shares of Organon & Co. from an “underweight” rating to a “neutral” rating and raised their price objective for the stock from $5.00 to $14.00 in a research report on Tuesday, April 28th. Five research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Organon & Co. has a consensus rating of “Reduce” and a consensus target price of $11.40.

Check Out Our Latest Analysis on OGN

Insider Buying and Selling at Organon & Co.

In other Organon & Co. news, SVP Lynette Holzbaur bought 26,448 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were bought at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the acquisition, the senior vice president directly owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. The trade was a 100.17% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.62% of the stock is owned by corporate insiders.

About Organon & Co.

(Free Report)

Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.

In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.